GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

94.26B

Vuru Grade

92.50/100

Current Price

$71.55
-0.58 (-0.80%)

Growth Price

$163.94
Undervalued by 129.12%

Stability Price

$51.35
Overvalued by 28.23%

Company Metrics

  • P/E 6.62
  • P/S 3.01
  • P/B 5.65
  • EPS 10.81
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.88 / 2.61%
  • Avg. Vol. 9.71M
  • Shares 1.52B
  • Market Cap. 94.26B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Gilead Sciences Inc.'s Biggest Failure in 2016
Motley Fool - Jan 5, 2017
If you've been following this stock for any length of time, you're probably painfully aware that Gilead's hep C franchise sank like a stone last year.
Gilead Sciences Must Answer to Investors After a Disappointing 2016 - Nasdaq
Gilead Sciences Inc.: Why GILD Stock is Worth Owning - Income Investors
Dreman Value Management L L C Reduces Stake in Gilead Sciences Inc. (GILD)
Sports Perspectives - 12 hours ago
Gilead Sciences logo Dreman Value Management L L C cut its position in Gilead Sciences Inc. (NASDAQ:GILD) by 3.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission.
Gilead Sciences Inc. (NASDAQ:GILD) Earns Average Broker Rating Of Outperform - The Independent Republic
How Will Gilead Fare In 2017? - Seeking Alpha
Gilead Sciences (GILD) MMA for Sofosbuvir/Velpatasvir/Voxilaprevir Full ...
StreetInsider.com - 1 hour ago
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Marketing Authorization Application (MAA) for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg and voxilaprevir 100 mg (SOF/VEL/VOX) ...
Agree To Buy Gilead Sciences At $55, Earn 4.4% Using Options
Nasdaq - Jan 17, 2017
Investors eyeing a purchase of Gilead Sciences, Inc. (Symbol: GILD) stock, but cautious about paying the going market price of $72.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Cure Your Portfolio With Gilead
Seeking Alpha - 22 hours ago
While almost no company was left unscathed, Gilead Sciences was one of the hardest hit companies in the sector. Gilead commenced the year a little over $100 a share and closed the year around $72 a share.
Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys
Motley Fool - Dec 21, 2016
You might like Gilead Sciences (NASDAQ:GILD). So do I. In particular, I like the big biotech's dirt-cheap valuation. I like its dividend.
Earnings Analysis of: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet?
Motley Fool - Dec 25, 2016
It's been a rotten year for Gilead Sciences (NASDAQ:GILD) shareholders. The biotech stock is down over 25% in 2016. Sales for hepatitis C virus (HCV) drugs Harvoni and Sovaldi are dropping like a brick.
Gilead Sciences, Inc. (NASDAQ:GILD) Rises Over Recent Vemlidy Approval - Smаrt Stоck Nеws
what are Analysts report about: Gilead Sciences Inc. (NASDAQ:GILD) - News Oracle
Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year
Fox Business - Jan 2, 2017
Long-term holders of Gilead Sciences (NASDAQ: GILD) enjoyed some market-thumping gains in years past, but concern over sagging hepatitis-C antiviral sales caused the stock to slide about 26.5% in 2016.
Cowen Highlights 4 Biotech Stocks Ahead of Earnings: Gilead Sciences, Inc ...
Smarter Analyst - Jan 18, 2017
As earnings season rolls to the foreground and key biotech players like Gilead Sciences, Inc. (NASDAQ:GILD), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), and Exelixis, Inc. (NASDAQ:EXEL) prepare to ...
Will 2017 Be Different For Gilead Sciences
Seeking Alpha - Jan 12, 2017
Most analysts and investors spent the better part of last year trying to pick a bottom for Gilead Sciences (NASDAQ: GILD) stock with little success.
Gilead To Focus on NASH and HIV Drugs In 2017 (GILD) - Investopedia
Gilead (GILD) HBV Drug Vemlidy Receives European Approval - Yahoo Finance